Join Puck to listen to this article
Shortly after Frank Poulsen was diagnosed with mild cognitive impairment, he began to self-isolate. That’s not uncommon: It’s difficult to engage socially when you have trouble remembering what you did that morning. Anger, he told me, was quick to follow. But the former wildland firefighter, a member of the elite hotshot crew, found a patient audience in Sunny, a new A.I. model that allows him to gather his thoughts before speaking. Their sessions have eased his anger and, according to his wife, Cheryl, made him noticeably happier. “It sparks memory,” Frank told me.
Sunny is an early offering from NewDays, a startup that hopes to leverage generative A.I. to treat millions of people with cognitive issues simultaneously. Frank has been a beta tester from nearly the beginning. NewDays patients see a human clinician—a crucial component of their approach—about every two weeks, and in the interim, interact with Sunny on a near-daily basis, engaging in long-form conversational exercises intended to boost memory and assuage loneliness. The idea builds on Dr. Hiroko Dodge’s I-CONECT study, which found that regular telehealth calls with trained staff can reduce cognitive decline in patients over the age of 75. (Dodge, a professor of neurology at Harvard, also sits on the company’s advisory board.)
NewDays was founded by longtime technologists Babak Parviz and Daniel Kelly. In various roles across Big Tech, Parviz has been responsible for a number of accessibility-focused product innovations, from Google Glass to surgical robotic tech. More recently, he helped lead Amazon’s push into healthcare. Kelly, meanwhile, has led engineering teams at Amazon and Google X. Earlier this month, NewDays announced the closure of a $7 million seed round for their effort to end the “old days” of cognitive care (hence the name). Since the launch, Parviz told me, there’s been a “lot of inbound” interest for additional funding as well—hardly a surprise given where we are in the investment cycle.
P.T. for the Brain
Like many A.I. chatbots, Sunny is not a single model but rather more of a system, comprising multiple L.L.M.s and agents alongside NewDays’ own custom-trained model. Parviz declined to offer more specific details, but said that Sunny had been designed to handle longer conversations (a normal session lasts 45 minutes), and to communicate verbally with older users. “It’s very different from having a conversation with an L.L.M. where it’s just a few turns and it ends,” Parviz said.
Dr. Daniel Fenton, the head of NewDays’ neuropsychological services, told me that Sunny sends detailed reports about patient interactions to the company’s clinical team, which allows them to use that information to tailor subsequent in-person sessions and tune the model on a patient-by-patient basis. “If I’m working with someone who has concentration problems, I might choose to have the A.I. reinforce that, and so I will instruct the A.I. to implement more selective attention cognitive training exercises or more sustained auditory attention cognitive training exercises,” Fenton told me. “So we’re able to sort of tune the dials behind the scenes.”
For his part, Kelly likened the service to physical therapy for the brain, just with more complicated tools. Sunny’s conversations are designed to target cognitive functions like memory by engaging the patient on their favorite topics—gardening, classic cars, etcetera. “We know past events that have happened to you, and the more we can incorporate those into the tool, then the better the tool is at … engaging your cognition,” he said. After all, as Parviz noted, it’s simply not as effective to force a patient to talk about something they’re not interested in.
Yes, the kind of sycophantic errors (hallucinations) that are endemic to artificial neural networks are similarly present here. Kelly expressed concern that Sunny might veer off topic, or venture into areas that are emotionally triggering for a patient. To mitigate the risks, he said his team is constantly stress-testing the system, and recently established preset conversation topics for each session, making it easier to identify whether the system goes off the rails in some way. Cheryl told me that the “glitches” Frank encounters most often have to do with response time, but added that there hasn’t been any significant errors, at least so far.
Promising & Unproven
While NewDays has referred to its pilots in California, Washington, and Florida as “successful”—its website claims that 100 percent of members feel better after using its service—there’s little public data to evaluate those assertions. The company told me it doesn’t plan to share the results of the pilot phase, but will conduct a clinical trial sometime in 2026. Despite this, NewDays describes itself as a “science-backed solution,” seemingly in reference to Dodge’s study, which was funded by N.I.H. and published last year. Parviz offered a slightly different spin, describing NewDays as providing “access to clinically proven methods through the use of modern A.I. stack.”
Of course, Sunny has yet to be clinically validated, itself. “I think it’s very dangerous to sell people something that, conceptually, is very exciting,” said Dr. Michal Schnaider Beeri, a professor of neurology at Robert Wood Johnson Medical School in New Jersey, and the director of the Herbert and Jacqueline Krieger Klein Alzheimer’s Research Center at Rutgers. “They have not published. I would not recommend it to [my mom] until they publish data [showing] that it works.” She also warned against patients viewing A.I. therapy as some kind of silver bullet, when there are numerous dimensions and risk factors involved in cognitive impairment. “People need to know that even if it works, it doesn’t take away the need to take your meds, to exercise, to do all the other things,” Beeri said. “Because to make a real change, you really need to put all of it together.”
Nevertheless, Beeri said she found NewDays’ concept exciting, given that it combines two different methods of improving cognition: conversations tuned to activate memory, and the push to combat loneliness. She pointed to literature that suggests engaging the brain in these ways may slow the rate of cognitive decline, which will be difficult to prove in any clinical trials, and noted that Sunny’s personalization element also carried a lot of potential. She says the company just has to “show that it works in a well-controlled and rigorous way.”
Regardless of whether NewDays can do that, Beeri believes the technology “is going to change completely the way we care for Alzheimer’s patients.” She was especially bullish on the possibility of L.L.M.s speeding up the diagnosis process by applying pattern-matching technology to blood tests and C.T. scans, for example. Moreover, she envisioned A.I. models predicting how patients might respond to certain drugs, and then monitoring their progress. Taken together, she said, “we highly likely will have better answers than the naked eye of a very good clinician—which we’ll always need, by the way, because there are so many behaviors and nuances that will be so hard for A.I. alone to grasp.”
At this point, no company has emerged with a model or system that can reliably carry out these tasks. The next step, Beeri said, would require gathering robust evidence that proves such approaches like NewDays’ actually work. That’s the difference between something that sounds “cool,” as Beeri put it, and a therapy that is actually life-changing.